Coronary interventions - Mini focus on left main revascularisation

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

EuroIntervention 2022;17:1477-1487. DOI: 10.4244/EIJ-D-21-00415

Hironori Hara
Hironori Hara1,2, MD; Hideyuki Kawashima1,2, MD; Masafumi Ono1,2, MD; Kuniaki Takahashi1, MD; Michael J. Mack3, MD; David R. Holmes Jr4, MD; Marie-Claude Morice5, MD; Piroze M. Davierwala6, MD; Friedrich W. Mohr6, MD, PhD; Daniel J.F.M. Thuijs7, MD; Arie Pieter Kappetein2, MD, PhD; Neil O'Leary8, PhD; David van Klaveren9,10, PhD; Yoshinobu Onuma2, MD, PhD; Patrick W. Serruys2,11, MD, PhD
1. Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 2. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; 3. Department of Cardiothoracic Surgery, Baylor Scott & White Health, Dallas, TX, USA; 4. Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN, USA; 5. Unité de Cardiologie, Hôpital Privé Jacques Cartier, Générale de Santé Massy, Massy, France; 6. University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany; 7. Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands; 8. Health Research Board Clinical Research Facility, Department of Medicine, NUIG, Galway, Ireland; 9. Department of Public Health, Center for Medical Decision Making, Erasmus MC, Rotterdam, the Netherlands; 10. Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; 11. NHLI, Imperial College London, London, United Kingdom

Background: Creatinine clearance (CrCl) is an independent determinant of mortality in predictive models of revascularisation outcomes for complex coronary artery disease.

Aims: This study aimed to investigate the impact of preprocedural biological markers on 10-year mortality following coronary revascularisation.

Methods: The SYNTAX Extended Survival (SYNTAXES) study evaluated the 10-year vital status follow-up of 1,800 patients with de novo three-vessel (3VD) and/or left main coronary artery disease (LMCAD) randomised to include percutaneous or surgical coronary revascularisation. The associations between mortality and preprocedural C-reactive protein (CRP), haemoglobin, HbA1c, CrCl, fasting triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were analysed.

Results: Out of 1,800 patients, 460 patients died before the 10-year follow-up. CRP, HbA1c and CrCl with threshold values of ≥2 mg/L, ≥6% (42 mmol/mol) and <60 ml/min, respectively, were associated with 10-year all-cause death (adjusted hazard ratio [95% confidence interval]: 1.35 [1.01-1.82], 1.51 [1.16-1.95], and 1.46 [1.07-2.00], respectively). There was no significant interaction between the biological markers on all-cause mortality and the type of revascularisation. Preprocedural lipid markers were not significantly associated with 10-year all-cause death, but the non-use of statins was a determinant factor of worse prognosis (adjusted hazard ratio [95% confidence interval]: 1.68 [1.26-2.25]).

Conclusions: Preprocedural biomarkers, such as CRP and HbA1c, are associated with long-term mortality post revascularisation, regardless of the revascularisation technique. Conventional lipidic biomarkers associated with high-risk of cardiovascular events seem to be effectively mitigated by the long-term use of statins, whereas the non-use of statins was a factor of a worse prognosis, emphasising the importance of pharmacological treatment. Trial registration: SYNTAXES NCT03417050. SYNTAX NCT00114972.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

left mainmultiple vessel diseaserisk stratification
Read next article
Napkin ring formation in culotte stenting using current-generation drug-eluting stents in left main coronary artery bifurcation

Latest news